SARA GALIMBERTI - CURRICULUM VITAE.
Sara Galimberti was born in La Spezia-Italy, the 08/08/1967.
EDUCATION/TRAINING
1986-1992:University of Pisa and “Scuola Superiore di Studi Universitari e Perfezionamento S.Anna”: Medicine and Surgery
1992-1995: Post-graduate course in experimental medicine
1996: PhD
1999: post-graduate degree in hematology
2000: Physician Dirigent at Hematology Unit of Pisa
2001-2015: Researcher at the Clinical and Experimental Medicine Department, Haematology Section, University of Pisa and Scientific Responsible for the Molecular Section of the Hematology Division.
From the 1994 she followed several national trials about acute leukemia and CLL coordinated by the GIMEMA Italian Group.
In the 1999-2001 she worked for the MURST project, coordinated by Prof. S. Tura about Minimal residual disease in multiple myeloma patients candidates to autologous transplantation.
From the 2001, she is the scientific responsible for the molecular laboratory of the Haematology Division; this laboratory is the referee for diagnostic molecular tests for all hospitals in the West coast of Tuscany and is one of the 4 laboratories of the FIL MRD NETWORK, referee centers for the assessment of the minimal residual disease in the clinical trials coordinated by the Italian Foundation for Lymphoma Studies (FIL).
Dr. Galimberti was involved in many clinical trials, especially in CML, according to GMP rules. In the CML setting, Dr. Galimberti is responsible of the hematological aspects of the TIKLET trial (pharmacokinetics, pharmacodinamics of TKIs).
Principal research areas: multidrug resistance, minimal residual disease, histone deacetylase inhibitors, arsenic trioxide, bortezomib, gamma delta lymphocytes, methylation, aGVHD, CML.
Finally, Dr. Galimberti participated to many meetings and international congresses often as invited speaker and she is referee for several peer revised journals.
EXPERIENCES
1993: Molecular Laboratory of Prof. Giuseppe Saglio (Orbassano – Turin-Italy)
2001: Cytogenetic-Molecular Laboratory of the Helsinki University.
2003: Molecular Laboratory of Prof. Giuseppe Saglio (Orbassano – Turin-Italy) In July 2007: Karolinska Institutet in Stockholm with Dr. Eva Hellstrom-Lindberg and Prof. Moustapha Hassan.
COLLABORATIONS
Hematology of Catania, Ancona, Pesaro, Milano, Reggio Calabria, Torino, Bologna, Roma
Karolinska Stockholm
BC Cancer Research Centre,Vancouver, BC, Canada
TEACHING:
laboratory techniques, dietists at Medical University of Pisa. Schools of PhD: genetics and microbiology, and development. School of specialization in hematology. Tuscany PhD: GeNOMEC. Master in Experimentation of Drugs of the Pisa University.
HONORS:
1998: Rotary prize for young researchers
2013: Regional referent for the Italian Society of Hematology
2014: Member of Scientific Board of the LABNET (network for CML studies); representative for the Tuscany in the Italian Society of Hematology (SIE) and member of the board of the Italian Society of Experimetal Hematology (SIES)
RESEARCH FEES
Research contracts with Celgene, Novartis, Roche
Dr. Galimberti was involved in many clinical trials, especially in CML, according to GMP rules.
Principal research areas: multidrug resistance, minimal residual disease, histone deacetylase inhibitors, arsenic trioxide, bortezomib, gamma delta lymphocytes, methylation, aGVHD.
Finally, Dr. Galimberti participated to many meetings and international congresses often as invited speaker and she is referee for several peer revised journals.